|
Adult Langerhans Cell Histiocytosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A mutational study by massive sequencing identified the Val600Glu (V600E) BRAF mutation in the Langerhans cell histiocytosis lesions, but no molecular alterations were found in the reticulohistiocytoma lesions.
|
31006900 |
2019 |
|
Adult Langerhans Cell Histiocytosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
An activating missense mutation in codon 600 of exon 15 (V600E) of BRAF gene has been identified in multiple neoplasms including melanoma, colorectal carcinoma, papillary thyroid carcinoma, hairy cell leukemia, and Langerhans cell histiocytosis.
|
29271794 |
2019 |
|
Adult Langerhans Cell Histiocytosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Primary oral manifestation of Langerhans cell histiocytosis refractory to conventional therapy but susceptible to BRAF-specific treatment: a case report and review of the literature.
|
31666812 |
2019 |
|
Adult Langerhans Cell Histiocytosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To the best of our knowledge, this case is the first case to report two different BRAF mutations in tissues of a Langerhans cell histiocytosis and a papillary thyroid carcinoma co-existing in the thyroid gland.
|
30795755 |
2019 |
|
Adult Langerhans Cell Histiocytosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
BRAF V600E and Pten deletion in mice produces a histiocytic disorder with features of Langerhans cell histiocytosis.
|
31527903 |
2019 |
|
Adult Langerhans Cell Histiocytosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Vemurafenib currently has Food and Drug Administration approval for the treatment of BRAF V600E+ metastatic melanoma in adults, but recent discoveries of BRAF V600E in more than half of tested Langerhans cell histiocytosis lesions have prompted clinical trials of vemurafenib therapy for children with refractory, multisystem Langerhans cell histiocytosis.
|
30216522 |
2018 |
|
Adult Langerhans Cell Histiocytosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET Study.
|
29188284 |
2018 |
|
Adult Langerhans Cell Histiocytosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The use of BRAF V600E mutation-specific immunohistochemistry in pediatric Langerhans cell histiocytosis.
|
28219109 |
2018 |
|
Adult Langerhans Cell Histiocytosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Novel activating BRAF fusion identifies a recurrent alternative mechanism for ERK activation in pediatric Langerhans cell histiocytosis.
|
28748614 |
2018 |
|
Adult Langerhans Cell Histiocytosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Frequency of MAP2K1, TP53, and U2AF1 Mutations in BRAF-mutated Langerhans Cell Histiocytosis: Further Characterizing the Genomic Landscape of LCH.
|
29649018 |
2018 |
|
Adult Langerhans Cell Histiocytosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
New somatic BRAF splicing mutation in Langerhans cell histiocytosis.
|
28679432 |
2017 |
|
Adult Langerhans Cell Histiocytosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
BRAF mutations have been reported in 40-70% of cases and MAP2K1 mutations have been found in BRAF-negative cases, supporting that Langerhans cell histiocytosis is a true neoplasm, at least in mutated cases.
|
28084334 |
2017 |
|
Adult Langerhans Cell Histiocytosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Effective BRAF inhibitor vemurafenib therapy in a 2-year-old patient with sequentially diagnosed Langerhans cell histiocytosis and Erdheim-Chester disease.
|
28182116 |
2017 |
|
Adult Langerhans Cell Histiocytosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The aim of this retrospective monocentric study in a national reference centre is to describe the clinical characteristics, quality of life, BRAF mutation status and outcomes of skin involvement in adult patients with Langerhans cell histiocytosis.
|
28421232 |
2017 |
|
Adult Langerhans Cell Histiocytosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
BRAF V600 mutations in Langerhans cell histiocytosis with a simple and unique assay.
|
27094161 |
2016 |
|
Adult Langerhans Cell Histiocytosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Alternative genetic mechanisms of BRAF activation in Langerhans cell histiocytosis.
|
27729324 |
2016 |
|
Adult Langerhans Cell Histiocytosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
BRAF Mutation Correlates With High-Risk Langerhans Cell Histiocytosis and Increased Resistance to First-Line Therapy.
|
27382093 |
2016 |
|
Adult Langerhans Cell Histiocytosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Treatment of Langerhans cell histiocytosis: role of BRAF/MAPK inhibition.
|
26637773 |
2015 |
|
Adult Langerhans Cell Histiocytosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Langerhans cell histiocytosis in Chinese adults: absence of BRAF mutations and increased FOXP3(+) regulatory T cells.
|
25031736 |
2014 |
|
Adult Langerhans Cell Histiocytosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
BRAF V600E expression in Langerhans cell histiocytosis: clinical and immunohistochemical study on 25 pulmonary and 54 extrapulmonary cases.
|
24625419 |
2014 |
|
Adult Langerhans Cell Histiocytosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Activating BRAF V600E mutation in aggressive pediatric Langerhans cell histiocytosis: demonstration by allele-specific PCR/direct sequencing and immunohistochemistry.
|
25118810 |
2014 |
|
Adult Langerhans Cell Histiocytosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Localized Langerhans cell histiocytosis of the thymus with BRAF V600E mutation: a case report with immunohistochemical and genetic analyses.
|
24703101 |
2014 |
|
Adult Langerhans Cell Histiocytosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
High prevalence of somatic MAP2K1 mutations in BRAF V600E-negative Langerhans cell histiocytosis.
|
24982505 |
2014 |
|
Adult Langerhans Cell Histiocytosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In this issue of Blood, Haroche and colleagues report significant therapeutic activity of the BRAF inhibitor, vemurafenib, in 3 patients with rare histiocytic conditions, Erdheim-Chester disease and Langerhans cell histiocytosis.
|
23449613 |
2013 |
|
Adult Langerhans Cell Histiocytosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation.
|
23258922 |
2013 |